{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Benedict K"],"funding":["Intramural CDC HHS"],"pagination":["myaf049"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12281149"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["63(6)"],"pubmed_abstract":["We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts."],"journal":["Medical mycology"],"pubmed_title":["Economic burden of fungal diseases in the United States."],"pmcid":["PMC12281149"],"funding_grant_id":["CC999999"],"pubmed_authors":["Gold JAW","Benedict K","Chiller T","Lyman M"],"additional_accession":[]},"is_claimable":false,"name":"Economic burden of fungal diseases in the United States.","description":"We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-03-27T16:53:46.729Z","creation":"2025-08-28T03:08:56.057Z"},"accession":"S-EPMC12281149","cross_references":{"pubmed":["40455586"],"doi":["10.1093/mmy/myaf049"]}}